Skyrizi (risankizumab) for sale – Buy Skyrizi (risankizumab) online
What is Skyrizi (risankizumab) for?
Skyrizi (risankizumab) is an interleukin-23 antagonist indicated to treat adults with:[1]
- Plaque psoriasis that is moderate to severe in patients who are candidates for systemic therapy or phototherapy.
- Active psoriatic arthritis
It is available prefilled syringe and pen containing 150 mg/mL of risankizumab.[1]
How does Skyrizi (risankizumab) work?
The active ingredient in Skyrizi, risankizumab, is a human monoclonal antibody, a type of protein, that binds to the cytokines interleukin (IL)-23. Cytokines play a role in signaling in a cell, especially in inflammation. Dysregulated production of and IL-23 were found to be very important in the development of specific diseases, such as psoriasis.[2]
By binding to IL-23, tildrakizumab will block their action, and thereby slow down inflammation.[1,2]
Where has Skyrizi (risankizumab) been approved?
Skyrizi (risankizumab) was approved by:
- The Food and Drug Administration (FDA), USA
- The European Medicines Agency (EMA)
- Therapeutic Goods Administration (TGA)
- On July 23, 2019 to treat moderate to severe plaque psoriasis.[7]
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team. /contact-us
How is Skyrizi (risankizumab) taken?
The standard dosage is:[1]
- The first two doses of 150 mg are given 4 weeks apart
- The following doses are given every 12 weeks
Skyrizi is administered as an injection beneath the skin (subcutaneous).[1]
Skyrizi can be taken in a treatment center or at home after you receive training from your doctor.[1]
Complete information about Skyrizi (risankizumab) dosage (modification) and administration can be found in the official prescribing information listed in our references section.[1]
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Skyrizi (risankizumab)?
Common adverse reactions
The most common side effects (≥1% of patients) listed in the prescribing information include:[1]
- Upper respiratory infections
- Headache
- Fatigue
- Injection site reactions
- Tinea infections
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:[1]
- Hypersensitivity reaction
- Infections
- Tuberculosis (TB)
Use in a specific population
Skyrizi (risankizumab) may harm your unborn baby when administered to a pregnant woman. Skyrizi may affect fertility in females and males who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.[1]
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.[1]
References
1. Full prescribing information [FDA]: Skyrizi (risankizumab) [PDF]
Novartis, Apr 2019
2. Targeting IL-23 in psoriasis: current perspectives
Fotiadou C, Psoriasis (Auckl.), Jan 4, 2018
3. AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
FDA press release, Apr 2019
4. U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
FDA press release, Jan 2022
5. European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
EMA press release, Apr 2019
6. AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
EMA press release, Nov 2021
7. AbbVie welcomes Therapeutic Goods Administration (TGA) – Regulatory Approval of SKYRIZI™ (risankizumab) [PDF]
TGA press release, Jul 2019
Reviews
There are no reviews yet.